Selecting the TP method
Example 13 — Pharma R&D — milestone pricing
Draft (June 2026) · Annex I · Example 13 · ¶51–55 · Pharma Co
OECD discussion draft, June 2026 (not final)At a glance
Company A engages a specialised affiliate (Company B) to run clinical trials using its own proprietary computational biology. The risk of R&D failure is borne by Company A, but Company B contributes unique IP and proven outcome-shortening capability. How is Company B compensated?
The parties
Company A
R&D principal · owns and exploits drug IP · bears R&D failure riskdata analysis & trials
Company B
Clinical trials with proprietary analytics IPWhat happens
- Pharma Co centralises drug development in Company A (subsidiary that owns and exploits drug IP).
- Company A engages Company B for data analysis and patient stratification using Company B's own IP and track record.
- At contract date, the probability that any new drug succeeds is highly uncertain.
- Compensation is structured to keep Company B operating on a rolling basis and to incentivise specific clinical milestones.
Analysis
Company A owns the drug IP and bears the risk of R&D failure. Company B brings its own analytics IP, designs and runs the trials, takes the related risks — and has a track record of speeding up timelines.
What pricing structure fits Company B?
OECD analysis · Milestone-based remuneration
Based on industry practices documented by Company A, the remuneration is structured to ensure Company B can continue its operations on a rolling basis while incentivising successful clinical milestones, taking into account the risks Company B assumes and the IP it uses in providing the services.
Key takeaway
Where a service provider contributes unique IP and bears meaningful risks, pure cost-plus is rarely arm's length. Structures that combine baseline coverage with success-linked rewards can better reflect the parties' contributions.
Related: Chapter VI (intangibles) · Example 15 (contract research vs. unique R&D)